Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 197

Results For "TN"

3018 News Found

Glenmark receives ANDA approval for Sodium Phenylbutyrate Tablets
Drug Approval | November 03, 2022

Glenmark receives ANDA approval for Sodium Phenylbutyrate Tablets

Glenmark’s Sodium Phenylbutyrate Tablets USP, 500 mg, will be distributed in the U.S. by Glenmark Pharmaceuticals USA.


Lonza launches new capsule to deliver acid-sensitive API to the intestine
News | November 02, 2022

Lonza launches new capsule to deliver acid-sensitive API to the intestine

Innovative Capsugel Enprotect capsule can simplify the manufacturing process to accelerate drug development and expedite first-in-human timelines


Lonza and Singzyme to accelerate development of Bioconjugates
News | November 01, 2022

Lonza and Singzyme to accelerate development of Bioconjugates

Through the collaboration, Lonza will gain access to Singzyme’s enzymatic conjugation platform enabling the site-specific binding of payloads with peptidic linkers to proteins of interest


Glenmark Pharmaceuticals launches Fingolimod Capsules in US
News | November 01, 2022

Glenmark Pharmaceuticals launches Fingolimod Capsules in US

According to IQVIA sales data for the 12-month period ending September 2022, the Gilenya Capsules, 0.5 mg market achieved annual sales of approximately US $1.8 billion


NHA organises workshop to accelerate adoption of ABDM
Policy | November 01, 2022

NHA organises workshop to accelerate adoption of ABDM

The participants discussed the latest developments under ABDM that shall enable true interoperability in the health sector and how effective adoption of ABDM can pave the way towards Universal Health Coverage


Ashland injectable pharmaceutical excipient accepted into FDA Novel Excipient Review Pilot Program
Drug Approval | November 01, 2022

Ashland injectable pharmaceutical excipient accepted into FDA Novel Excipient Review Pilot Program

The voluntary program is the first time the FDA will allow excipient manufacturers to obtain review of certain novel excipients prior to their use in drug formulations.


Aptar Pharma completes Phase I global injectables expansion program
News | November 01, 2022

Aptar Pharma completes Phase I global injectables expansion program

The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint.


Sustaining growth momentum is key for Navin Fluorine: ICICI Securities
News | October 31, 2022

Sustaining growth momentum is key for Navin Fluorine: ICICI Securities

NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.


USFDA determines inspection classification of Jubilant Pharmova's Roorkee facility
News | October 31, 2022

USFDA determines inspection classification of Jubilant Pharmova's Roorkee facility

The company currently supplies one product to the US market that contributes low- single digit revenue to Jubilant Pharmova revenue


USFDA issues Form 483 for Parawada unit of Laurus Labs
Drug Approval | October 30, 2022

USFDA issues Form 483 for Parawada unit of Laurus Labs

The observation is procedural in nature and the company will address the observation within stipulated timelines.